Clinical Endocrinology最新文献

筛选
英文 中文
Brain MRI Findings and Factor Associated With Clinical Significant CNS Lesions in Girls Aged 6-8 With Central Precocious Puberty. 6-8岁中枢性性性早熟女孩的脑MRI表现及相关因素
IF 2.8 3区 医学
Clinical Endocrinology Pub Date : 2026-11-13 DOI: 10.1111/cen.70230
Vu Chi Dung, Nguyen Thi Hang, Pham Quang Duy, Bui Phương Thao, Cao Viet Tung, Nguyen Ngoc Khanh, Do Thi Thanh Mai, Nguyen Thu Ha, Le Thi Kim Ngoc, Lương Thi Hong Hai, Tran Thi Thuy Linh, Bui Thi Huong, Do Thi Mo, Nguyen Hoang Lan, Can Thi Bich Ngoc
{"title":"Brain MRI Findings and Factor Associated With Clinical Significant CNS Lesions in Girls Aged 6-8 With Central Precocious Puberty.","authors":"Vu Chi Dung, Nguyen Thi Hang, Pham Quang Duy, Bui Phương Thao, Cao Viet Tung, Nguyen Ngoc Khanh, Do Thi Thanh Mai, Nguyen Thu Ha, Le Thi Kim Ngoc, Lương Thi Hong Hai, Tran Thi Thuy Linh, Bui Thi Huong, Do Thi Mo, Nguyen Hoang Lan, Can Thi Bich Ngoc","doi":"10.1111/cen.70230","DOIUrl":"https://doi.org/10.1111/cen.70230","url":null,"abstract":"<p><strong>Background: </strong>Brain magnetic resonance imaging (MRI) is recommended for selected girls with central precocious puberty (CPP). Routine brain magnetic resonance imaging (MRI) in girls aged 6-8 years with central precocious puberty (CPP) remains clinically controversial. Neurological features may help identify girls at higher risk, but whether basal luteinizing hormone (LH), a routinely measured marker of hypothalamic-pituitary-gonadal axis activation, provides additional information beyond age at diagnosis remains uncertain.</p><p><strong>Methods: </strong>In this retrospective cross-sectional study, 848 girls aged 6-8 years diagnosed with CPP underwent brain MRI at Vietnam National Children's Hospital between April 2021 and June 2026. Brain MRI findings were classified as clinically significant/pathological, uncertain/questionable significance, or incidental. Neurological characteristics were compared across the MRI categories. Logistic regression was used to identify factors associated with clinically significant MRI abnormalities. Sequential models evaluated whether basal LH provided additional information beyond age at diagnosis, with model fit and discrimination assessed using likelihood-ratio tests, Akaike information criterion (AIC) and area under the receiver operating characteristic curve (AUC).</p><p><strong>Results: </strong>Any brain MRI abnormalities were identified in 86 girls (10.1%), including 30 (3.5%) with clinically significant central nervous system (CNS) lesions, 14 (1.7%) with questionable findings and 42 (5.0%) with incidental findings. Neurological symptoms, signs or previous CNS history were more frequent among girls with clinically significant abnormalities than among those with uncertain or incidental findings (30.0%, 7.1% and 4.8%, respectively; p = 0.012). Basal LH was independently associated with clinically significant MRI abnormalities (adjusted OR 1.30 per IU/L, 95% CI 1.14-1.47; p < 0.001. Adding basal LH to age at diagnosis significantly improved model fit (AIC 247.79 vs. 259.78; likelihood-ratio p = 0.0002), although discrimination remained modest (AUC 0.654 vs. 0.550 for age alone, p = 0.055). Bone-age advancement did not provide significant additional information.</p><p><strong>Conclusions: </strong>In girls aged 6-8 years with CPP, brain MRI abnormalities were identified in approximately 1 in 10 girls, but most were incidental or of uncertain clinical significance. Clinically significant abnormalities were enriched among girls with neurological features. Basal LH provided incremental information beyond age at diagnosis but had limited discriminatory performance. These findings support a risk-stratified approach to brain MRI in girls aged 6-8 years with CPP, with careful neurological assessment remaining central to imaging decisions.</p>","PeriodicalId":10346,"journal":{"name":"Clinical Endocrinology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149402596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence, Incidence, Clinical Presentation, and Treatment of Polyendocrine Metabolic Ovarian Syndrome in Primary Care in the United Kingdom Between 1998 and 2025. 1998年至2025年英国多内分泌代谢性卵巢综合征的患病率、发病率、临床表现和治疗
IF 2.8 3区 医学
Clinical Endocrinology Pub Date : 2026-11-11 DOI: 10.1111/cen.70231
Samantha B Shapiro, Oriana H Y Yu, Michael H Dahan, Laurent Azoulay
{"title":"Prevalence, Incidence, Clinical Presentation, and Treatment of Polyendocrine Metabolic Ovarian Syndrome in Primary Care in the United Kingdom Between 1998 and 2025.","authors":"Samantha B Shapiro, Oriana H Y Yu, Michael H Dahan, Laurent Azoulay","doi":"10.1111/cen.70231","DOIUrl":"https://doi.org/10.1111/cen.70231","url":null,"abstract":"<p><strong>Objective: </strong>Polyendocrine metabolic ovarian syndrome (PMOS) is a multisystemic disorder with a wide range of health consequences. We sought to describe temporal trends in the prevalence and incidence of PMOS and to characterize its clinical presentation, comorbidity burden, and pharmacological management in primary care in the United Kingdom (UK) between 1998 and 2025.</p><p><strong>Design: </strong>Population-based matched cohort study using primary care records from the UK Clinical Practice Research Datalink.</p><p><strong>Patients: </strong>Females newly diagnosed with PMOS between the ages of 15 and 49 matched on age, general practice, calendar year of cohort entry, and duration of medical history to population controls without PMOS.</p><p><strong>Measurements: </strong>Annual prevalence and incidence of diagnosed PMOS; baseline prevalence and incidence of cardinal PMOS features and various comorbidities; and pre- and post-cohort entry prevalence of hormonal contraceptive, anti-androgen, ovulation-inducing drug, and metformin use.</p><p><strong>Results: </strong>The prevalence of diagnosed PMOS increased from < 0.1% in 1998 to 2.0% in 2025, with incidence rising from 0.1 to 3.6 per 1,000 person-years over the same period. Among 125,482 patients with newly diagnosed PMOS matched with an equal number of controls, patients with PMOS had higher baseline prevalence and incidence of cardinal features of PMOS, as well as diabetes, dyslipidemia, hypertension, cardiovascular and cerebrovascular disease, sleep apnea, thyroid disorders, endometriosis, uterine fibroids, chronic pain, depression, and anxiety. Use of anti-androgens, ovulation-inducing drugs, and metformin was substantially higher in patients with PMOS, especially in the year following diagnosis.</p><p><strong>Conclusions: </strong>PMOS is increasingly diagnosed in UK primary care and is associated with substantial multimorbidity and pharmacotherapy.</p>","PeriodicalId":10346,"journal":{"name":"Clinical Endocrinology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149393159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Growth Hormone Stimulation Testing in Childhood: Diagnostic Pathways and Discordant Results in a Tertiary Centre Cohort. 儿童生长激素刺激试验:第三中心队列的诊断途径和不一致的结果。
IF 2.8 3区 医学
Clinical Endocrinology Pub Date : 2026-11-10 DOI: 10.1111/cen.70232
Eimear M O'Connell, Maeve McDyer, Colm Costigan, Eirin Carolan, Nuala P Murphy
{"title":"Growth Hormone Stimulation Testing in Childhood: Diagnostic Pathways and Discordant Results in a Tertiary Centre Cohort.","authors":"Eimear M O'Connell, Maeve McDyer, Colm Costigan, Eirin Carolan, Nuala P Murphy","doi":"10.1111/cen.70232","DOIUrl":"https://doi.org/10.1111/cen.70232","url":null,"abstract":"<p><strong>Objective: </strong>Growth hormone stimulation tests (GHSTs) are central to the diagnosis of growth hormone deficiency (GHD) despite recognised limitations. Two failed GHSTs are recommended to confirm GHD; however, a single failed test may be considered sufficient in selected cases. This study aimed to describe GHST practice in a tertiary paediatric endocrine centre, to determine how often an initial subthreshold GHST was not followed by a final diagnosis of GHD and to assess the diagnostic performance of IGF-I, IGFBP-3 and the IGF-I/IGFBP-3 molar ratio.</p><p><strong>Design: </strong>Retrospective observational study.</p><p><strong>Patients: </strong>Seventy-three children who underwent GHST for suspected GHD at a tertiary Irish paediatric endocrinology centre.</p><p><strong>Measurements: </strong>Clinical, biochemical and radiological data were reviewed, including height, BMI, height velocity, IGF-I, IGFBP-3, bone age and GHST results.</p><p><strong>Results: </strong>GHD was diagnosed in 34 children (47%) and excluded in 39 (53%). Of 47 children with a first peak GH below 7 µg/L, GHD was subsequently excluded in 13, an apparent false-positive rate of 27.7% (95% CI 16.9-41.8). Six of the 13 had a severely subthreshold initial response (peak GH < 3 µg/L). Discordant results were clustered in peripubertal children. IGF-I had poor sensitivity and specificity (45.5% and 50.0%, respectively); IGFBP-3 had low sensitivity but high specificity (9.1% and 100%, respectively). The IGF-I/IGFBP-3 molar ratio did not differ between diagnostic groups.</p><p><strong>Conclusions: </strong>Approximately one in four children with a subthreshold first GHST was not ultimately diagnosed with GHD. These findings support the need for repeat testing before initiating treatment in children without independent evidence of pituitary disease.</p>","PeriodicalId":10346,"journal":{"name":"Clinical Endocrinology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149377786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Study of Visceral Adiposity Index and Free Androgen Index in Indian Women With PCOS: A Cross-Sectional Study. 印度多囊卵巢综合征妇女内脏脂肪指数和游离雄激素指数的横断面研究。
IF 2.8 3区 医学
Clinical Endocrinology Pub Date : 2026-11-09 DOI: 10.1111/cen.70228
Pieu Adhikary, Subhasish Pramanik, Shouvik Choudhury, Taruna Arora, Subhankar Chowdhury, Pranab Kumar Sahana, Mohd Ashraf Ganie, Vanita Suri, Prasanta Kumar Bhattacharya, Sarita Agrawal, Neena Malhotra, Rakesh Sahay, Roya Rozati, Puthiyaveettil Khadar Jabbar, Imtiyaz Ahmad Wani
{"title":"Study of Visceral Adiposity Index and Free Androgen Index in Indian Women With PCOS: A Cross-Sectional Study.","authors":"Pieu Adhikary, Subhasish Pramanik, Shouvik Choudhury, Taruna Arora, Subhankar Chowdhury, Pranab Kumar Sahana, Mohd Ashraf Ganie, Vanita Suri, Prasanta Kumar Bhattacharya, Sarita Agrawal, Neena Malhotra, Rakesh Sahay, Roya Rozati, Puthiyaveettil Khadar Jabbar, Imtiyaz Ahmad Wani","doi":"10.1111/cen.70228","DOIUrl":"https://doi.org/10.1111/cen.70228","url":null,"abstract":"<p><strong>Objective: </strong>PCOS is a complex endocrine disorder associated with metabolic and hormonal dysregulation. The visceral adiposity index (VAI) and free androgen index (FAI) have emerged as predictive markers for PCOS. This study aims to evaluate the role of VAI and FAI from the aspect of metabolic and hormonal imbalance in PCOS women from urban and rural areas of India.</p><p><strong>Study design and subjects: </strong>Women within the reproductive age of 18-40 years from both rural and urban areas of India were recruited in the study between November 2018 and July 2022 for this cross-sectional study. 12,100 women were approached to participate in the study, of whom 8993 subjects were enroled. After clinical examination and all investigations according to the protocol, 795 were PCOS cases, while 2475 were non-PCOS cases as per Rotterdam criteria. The PCOS group was segregated according to obesity.</p><p><strong>Measurements: </strong>Hormonal profile and ovarian morphology were evaluated along with anthropometric parameters. VAI, FAI, and Lipid Accumulation Product (LAP) were calculated based on biochemical parameters.</p><p><strong>Results: </strong>VAI and FAI were significantly elevated in PCOS compared to non-PCOS. VAI, FAI, and LAP were significantly increased in obese PCOS. VAI, independent of BMI, was significantly associated with the Ferriman Gallaway (FG) score, FBG, fasting insulin, and LAP, whereas FAI was associated with BMI and LAP.</p><p><strong>Conclusion: </strong>The study underscores that VAI may serve as the surrogate marker of PCOS, independent of obesity.</p>","PeriodicalId":10346,"journal":{"name":"Clinical Endocrinology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149377787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical, Biochemical, and Molecular Spectrum of Pseudohypoaldosteronism Type 1B in Indian Children: A Multicentric Case Series 印度儿童1B型假性醛固酮减少症的临床、生化和分子谱:一个多中心病例系列。
IF 2.8 3区 医学
Clinical Endocrinology Pub Date : 2026-11-01 Epub Date: 2026-08-04 DOI: 10.1111/cen.70196
Melkunte Shanthaiah Dhananjaya, Leenatha Jakkadi, Parvathy Lalitha, L Prasadh Rao, Hebbal Nagarajappa Vani, Avani Hegde, Rajneesh Reddy, Hitesh Reddy, Sandhya Nair, Vijaya Sarathi
{"title":"Clinical, Biochemical, and Molecular Spectrum of Pseudohypoaldosteronism Type 1B in Indian Children: A Multicentric Case Series","authors":"Melkunte Shanthaiah Dhananjaya,&nbsp;Leenatha Jakkadi,&nbsp;Parvathy Lalitha,&nbsp;L Prasadh Rao,&nbsp;Hebbal Nagarajappa Vani,&nbsp;Avani Hegde,&nbsp;Rajneesh Reddy,&nbsp;Hitesh Reddy,&nbsp;Sandhya Nair,&nbsp;Vijaya Sarathi","doi":"10.1111/cen.70196","DOIUrl":"10.1111/cen.70196","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Pseudohypoaldosteronism type 1 (PHA1) is a rare hereditary disorder characterised by aldosterone resistance leading to salt wasting, hyperkalaemia, and metabolic acidosis. Two forms are recognised: a milder renal form (PHA1A) due to <i>NR3C2</i> mutations and a severe systemic form (PHA1B) caused by biallelic mutations in epithelial sodium channel (<i>ENaC</i>) subunit genes. Data on Indian patients are scarce. This study describes the clinical, biochemical, and molecular characteristics and treatment outcomes of children with PHA1 from South India.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This multicentric retrospective series included nine children diagnosed with PHA1 across six tertiary care centres between 2022 and 2025. Clinical and biochemical data were extracted from hospital records. Plasma renin, aldosterone, cortisol, and 17-hydroxyprogesterone were measured at presentation. Genetic testing was performed using clinical exome sequencing, and variants were classified according to American College of Medical Genetics and Genomics (ACMG) guidelines.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>All nine patients had the systemic form (PHA1B). The median age at presentation was 14 days (interquartile range 5.5–42.5), and parental consanguinity was present in seven (78%). All presented with hyponatraemia and hyperkalaemia (median serum sodium 124 mEq/L; potassium 8.0 mEq/L). Eight (pathogenic/likely-pathogenic: 4, supporting: 4) homozygous variants were identified in <i>SCNN1A</i> (<i>n</i> = 2), <i>SCNN1B</i> (<i>n</i> = 3), and <i>SCNN1G</i> (<i>n</i> = 3); all were novel. Six patients (67%) died, mainly due to sepsis (<i>n</i> = 2) or treatment discontinuation (<i>n</i> = 4), while three remain stable on oral sodium supplementation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This first multicentric South Indian series highlights exclusive reporting of PHA1B, high early mortality, and major treatment challenges. Eight novel <i>ENaC</i> variants expand the genetic spectrum of PHA1B in India.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10346,"journal":{"name":"Clinical Endocrinology","volume":"105 6","pages":"634-642"},"PeriodicalIF":2.8,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148668543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Quality of Life Following Parathyroidectomy for Primary Hyperparathyroidism: Symptom Resolution Kinetics 原发性甲状旁腺功能亢进切除术后的生活质量:症状消退动力学。
IF 2.8 3区 医学
Clinical Endocrinology Pub Date : 2026-11-01 Epub Date: 2026-10-05 DOI: 10.1111/cen.70208
Jacquelyn Elise Fitzgerald Speer, Muhammad Osama Khan, Rongzhi Wang, Rachael Caretti, Niranjna Swaminathan, Andrea Gillis, Brenessa Lindeman, Sophie Dream, Herbert Chen
{"title":"Quality of Life Following Parathyroidectomy for Primary Hyperparathyroidism: Symptom Resolution Kinetics","authors":"Jacquelyn Elise Fitzgerald Speer,&nbsp;Muhammad Osama Khan,&nbsp;Rongzhi Wang,&nbsp;Rachael Caretti,&nbsp;Niranjna Swaminathan,&nbsp;Andrea Gillis,&nbsp;Brenessa Lindeman,&nbsp;Sophie Dream,&nbsp;Herbert Chen","doi":"10.1111/cen.70208","DOIUrl":"10.1111/cen.70208","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Primary hyperparathyroidism has been associated with significant symptom burden and impaired quality of life (QoL), yet the trajectory of recovery, especially in reoperative patients is incompletely characterised. This study evaluated longitudinal QoL changes following parathyroidectomy, characterising symptom resolution kinetics and comparing outcomes between cohorts. A prospective longitudinal cohort study was conducted between July 2021 and September 2023 at a single high volume tertiary centre. Patients with biochemically confirmed primary hyperparathyroidism who underwent parathyroidectomy were selected to complete the Primary Hyperparathyroidism Quality of Life questionnaire preoperatively, at 2 weeks postoperatively and then monthly through 12 months postoperative.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>There were 124 patients who completed at least one survey. Mean QoL scores improved significantly from baseline (31) to Month 1 (42; Cohen's <i>d</i> = 0.92). Symptom resolution generally occurred in over half of patients, with fatigue and bone pain resolving in 88% and 85% of patients by Month 12 respectively. Neuropsychiatric symptoms had a more variable postoperative resolution. Lower baseline QoL was the only predictor in postoperative QoL score improvement (<i>β</i> = −0.51, <i>p</i> &lt; 0.01). Reoperative parathyroidectomy was associated with similar QoL improvements but higher rates of persistent neurocognitive symptoms.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Parathyroidectomy results in both rapid and persistent improvement in QoL in patients with primary hyperparathyroidism. Symptom resolution was variable based on number of operations and symptom domain. Baseline QoL was the strongest predictor of benefit supporting the use of QoL as a preoperative metric to be considered in patients with primary hyperparathyroidism.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10346,"journal":{"name":"Clinical Endocrinology","volume":"105 6","pages":"616-622"},"PeriodicalIF":2.8,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149104979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Investigating a Mineralocorticoid Receptor Mediation of an Ultra-Short Feedback Loop Regulating Aldosterone Production in Humans 研究矿化皮质激素受体介导的超短反馈回路调节人类醛固酮的产生。
IF 2.8 3区 医学
Clinical Endocrinology Pub Date : 2026-11-01 Epub Date: 2026-08-12 DOI: 10.1111/cen.70189
Yan Emily Yuan, Gail K. Adler, Bernard Rosner, Annie Altman Merino, Ezgi Caliskan Guzelce, Gordon H. Williams, Jonathan S. Williams, Andrea V. Haas
{"title":"Investigating a Mineralocorticoid Receptor Mediation of an Ultra-Short Feedback Loop Regulating Aldosterone Production in Humans","authors":"Yan Emily Yuan,&nbsp;Gail K. Adler,&nbsp;Bernard Rosner,&nbsp;Annie Altman Merino,&nbsp;Ezgi Caliskan Guzelce,&nbsp;Gordon H. Williams,&nbsp;Jonathan S. Williams,&nbsp;Andrea V. Haas","doi":"10.1111/cen.70189","DOIUrl":"10.1111/cen.70189","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Preclinical studies suggest a novel aldosterone regulation pathway: the mineralocorticoid receptor (MR) on the adrenal cortex is a part of an MR-mediated ultra-short feedback loop regulating aldosterone production. Activation of MR on the adrenal decreases aldosterone; blockade of the MR increases aldosterone. Whether this regulatory pathway exists in humans is unknown.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This was a double-blinded, 3-way crossover study of 23 healthy participants on a low sodium diet (10 mEq/day). Participants received three study drugs in random order: MR antagonist (eplerenone), MR agonist (fludrocortisone), and placebo. Study drugs were administered at 6:30AM on three separate days with 48 h between each administration. After 90 min, participants received sequential infusions of angiotensin-II (ANGII) for 45 min followed 60 min later by cosyntropin for 45 min. Aldosterone was measured before and after each infusion. Multi-level mixed effects linear regression was used to analyze the data.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The change in aldosterone between baseline and post-cosyntropin infusion was greater after treatment with eplerenone as compared to placebo (5.16 ± 2.01 ng/dL, <i>p</i> = 0.01). There were no differences with fludrocortisone as compared to placebo. With ANGII stimulation, there were no differences in the change in aldosterone with either eplerenone or fludrocortisone versus placebo.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>In humans, MR antagonist treatment led to a greater increase in aldosterone in response to cosyntropin stimulation as compared to placebo, but not after ANGII stimulation. Future studies are needed to investigate the presence of a MR-mediated ultra-short feedback loop at the level of the adrenal gland regulating aldosterone production in humans.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Clinical Trial Registration Number</h3>\u0000 \u0000 <p>NCT02871648</p>\u0000 </section>\u0000 </div>","PeriodicalId":10346,"journal":{"name":"Clinical Endocrinology","volume":"105 6","pages":"610-615"},"PeriodicalIF":2.8,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148711496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Approach to The Patient With Combined Pituitary Hormone Deficiency Due to a Novel Homozygous LHX3 Variant 一种新型纯合子LHX3变异引起的合并垂体激素缺乏症患者的研究。
IF 2.8 3区 医学
Clinical Endocrinology Pub Date : 2026-11-01 Epub Date: 2026-08-05 DOI: 10.1111/cen.70198
Sirmen Kızılcan Çetin, İbrahim Dikmen, Elif Özsu, Zehra Aycan, Merih Berberoğlu, Zeynep Şıklar
{"title":"Approach to The Patient With Combined Pituitary Hormone Deficiency Due to a Novel Homozygous LHX3 Variant","authors":"Sirmen Kızılcan Çetin,&nbsp;İbrahim Dikmen,&nbsp;Elif Özsu,&nbsp;Zehra Aycan,&nbsp;Merih Berberoğlu,&nbsp;Zeynep Şıklar","doi":"10.1111/cen.70198","DOIUrl":"10.1111/cen.70198","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Context</h3>\u0000 \u0000 <p>Variants in LHX3, encoding a LIM-homeodomain transcription factor essential for pituitary and neuronal development, are a rare cause of combined pituitary hormone deficiency (CPHD). Affected patients typically exhibit deficiencies of growth hormone (GH), thyrotropin (TSH), prolactin (PRL), and gonadotropins, often accompanied by cervical spine rigidity or sensorineural hearing loss.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case Description</h3>\u0000 \u0000 <p>A 4.8-year-old boy presented with short stature and central hypothyroidism. Combined deficiencies of GH, TSH, and PRL were documented, while ACTH secretion remained intact. Cranial magnetic resonance imaging showed normal pituitary morphology. Neck mobility and audiological evaluation were unremarkable.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Evaluation</h3>\u0000 \u0000 <p>A targeted next-generation sequencing panel for panhypopituitarism was non-diagnostic. Whole-exome sequencing (WES) was performed at 10.5 years of age.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>WES identified a novel homozygous <i>LHX3</i> c.575 G &gt; A, p.(Arg192His) variant located within the homeodomain. Segregation analysis confirmed parental heterozygosity. A younger sister carrying the same homozygous variant exhibited a similar endocrine phenotype. Growth velocity normalized on recombinant human GH replacement.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This case expands the phenotypic spectrum of <i>LHX3</i>-related CPHD by demonstrating that a homeodomain missense variant may produce isolated endocrine deficiencies without structural, auditory, or motor abnormalities, and underscores the value of serial genetic re-evaluation in unexplained CPHD.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10346,"journal":{"name":"Clinical Endocrinology","volume":"105 6","pages":"643-650"},"PeriodicalIF":2.8,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148677262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lupus‑Associated Hypophysitis: A Narrative Systematic Review of Clinical, Radiological and Endocrine Features 狼疮相关垂体炎:临床、放射学和内分泌特征的系统性综述。
IF 2.8 3区 医学
Clinical Endocrinology Pub Date : 2026-11-01 Epub Date: 2026-08-03 DOI: 10.1111/cen.70197
Abdellatif Zhalka, Shadi Shinnawi, Rami Jabareen, Awad Karem, Muhammad Zahlaka
{"title":"Lupus‑Associated Hypophysitis: A Narrative Systematic Review of Clinical, Radiological and Endocrine Features","authors":"Abdellatif Zhalka,&nbsp;Shadi Shinnawi,&nbsp;Rami Jabareen,&nbsp;Awad Karem,&nbsp;Muhammad Zahlaka","doi":"10.1111/cen.70197","DOIUrl":"10.1111/cen.70197","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Lupus-associated hypophysitis is a rare but clinically important manifestation of systemic lupus erythematosus (SLE), characterised by heterogeneous pituitary dysfunction and inflammatory sellar changes that may mimic other pituitary disorders. Evidence is limited to isolated reports. We aimed to summarise clinical, radiological, endocrine features, management, and outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A narrative systematic review of MEDLINE, Embase, Web of Science, and Google Scholar to 10 November 2025. Reports were included if accepted SLE criteria were met and hypophysitis or hypothalamic–pituitary inflammation was attributed to SLE after exclusion of alternative sellar pathology. Demographic, clinical, endocrine, imaging, treatment, and outcome data were synthesised descriptively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Eleven cases (63% female; median age 23 years) were identified, most presenting at or near SLE diagnosis. Common symptoms included polyuria/polydipsia, fatigue, amenorrhoea, and headache. Arginine vasopressin deficiency (AVP-D) frequently coexisted with multi-axis anterior hypopituitarism. MRI typically demonstrated pituitary stalk thickening, gland enlargement, and loss of the posterior pituitary bright spot. High-dose glucocorticoids, with or without additional immunosuppression, led to improvement in most cases, although persistent adrenal and gonadal deficits were common; one patient died from severe hyponatraemia.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Lupus-associated hypophysitis is a rare manifestation of SLE with heterogeneous endocrine and radiological presentations that may create diagnostic challenges. Early endocrine evaluation and pituitary imaging are important in patients with suspected hypothalamic-pituitary involvement.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10346,"journal":{"name":"Clinical Endocrinology","volume":"105 6","pages":"660-666"},"PeriodicalIF":2.8,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148668670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pubertal Dynamics of Sertoli and Leydig Cell Dysfunction in Klinefelter Syndrome Klinefelter综合征青春期支持细胞和间质细胞功能障碍的动态变化。
IF 2.8 3区 医学
Clinical Endocrinology Pub Date : 2026-11-01 Epub Date: 2026-06-11 DOI: 10.1111/cen.70159
Tredez Axelle, Christine Lefevre, Simon Boussion, Cindy Colson, Iva Gueorguieva, Francois Marcelli, Anne Laure Barbotin, Pascal Pigny, Hamza Benderradji, Clara Leroy
{"title":"Pubertal Dynamics of Sertoli and Leydig Cell Dysfunction in Klinefelter Syndrome","authors":"Tredez Axelle,&nbsp;Christine Lefevre,&nbsp;Simon Boussion,&nbsp;Cindy Colson,&nbsp;Iva Gueorguieva,&nbsp;Francois Marcelli,&nbsp;Anne Laure Barbotin,&nbsp;Pascal Pigny,&nbsp;Hamza Benderradji,&nbsp;Clara Leroy","doi":"10.1111/cen.70159","DOIUrl":"10.1111/cen.70159","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Context</h3>\u0000 \u0000 <p>Klinefelter syndrome (KS), defined by a 47, XXY karyotype, is commonly associated with progressive testicular failure. The precise timing of Sertoli and Leydig cell dysfunction during puberty remains unclear.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To determine the onset and progression of testicular insufficiency during puberty in KS, and to assess whether diagnostic timing (prenatal vs postnatal) impacts pubertal phenotype.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a retrospective, single-centre study of 57 patients with KS aged 9–25 years, followed from the prepubertal period at Lille University Hospital. Longitudinal clinical and hormonal data were analysed according to pubertal stage rather than chronological age.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>All patients entered puberty spontaneously at a physiological age (mean 12.6 years), but experienced a slow pubertal tempo (mean duration: 4.08 years). Sertoli cell dysfunction appeared within 12 months of pubertal onset, with rising FSH and declining AMH and inhibin B levels. Inhibin B concentrations never reached the reference range for Tanner stage 5 and declined below the adult threshold (92 pg/mL) 2 years after pubertal onset. Leydig cell dysfunction, defined by elevated LH and low-normal testosterone, emerged after 36 months. At puberty completion, 94% had Sertoli cell insufficiency (i.e. FSH level &gt; 7.19 IU/L) and 80% had Leydig cell insufficiency (LH &gt; 5.88 IU/L). Postnatally diagnosed patients exhibited significantly higher LH (<i>p</i> = 0.03) and lower inhibin B (<i>p</i> = 0.01) levels.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Testicular insufficiency in KS begins approximately 18 months after pubertal onset, with Sertoli cell failure preceding Leydig cell decline. Early diagnosis and longitudinal monitoring are essential to guide endocrine management and to support individualized counselling regarding fertility preservation strategies, which should be considered according to pubertal stage rather than chronological age.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10346,"journal":{"name":"Clinical Endocrinology","volume":"105 6","pages":"623-633"},"PeriodicalIF":2.8,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cen.70159","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148223892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书